Akeso stock analysis 2026 | Price, valuation & outlook

Akeso

SEHK:9926

HK$ 126,40

+ HK$2,70 (2,18%)

126,40 HK$

+HK$2,70 (2,18%)

End-of-day quote: 03/27/2026

Akeso Stock Value

Analysts currently rate Akeso as Buy.

Buy

Akeso Company Info

EPS Growth 5Y

3,65%

Market Cap

HK$113,95 B

Long-Term Debt

HK$4,40 B

Annual earnings

03/26/2026 (A)

Dividend

HK$0,00

Dividend Yield

0,00%

Founded

2012

Industry

Health Care

Country

China

Website

Akeso

ISIN Number

KYG0146B1032

Website

http://www.akesobio.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$179,86

42.29%

Last Update: 03/27/2026

Analysts: 21

Highest Price Target HK$234,76

Average Price Target HK$179,86

Lowest Price Target HK$112,85

In the last five quarters, Akeso’s Price Target has risen from HK$26,40 to HK$67,74 - a 156,59% increase. Sixteen analysts predict that Akeso’s share price will increase in the coming year, reaching HK$179,86. This would represent an increase of 42,29%.

Top growth stocks in the health care sector (5Y.)

What does Akeso do?

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops therapeutics, particularly novel compounds such as ivonescimab (AK112), which targets PD-1 and VEGF pathways. Business Segments The company operates primarily through two main business segments: Research and Development (R&D) and Commercialization. Research and Development (R&D) The R&D segment focuses on the discovery and preclinical and clinical development...

Business Segments

The company operates primarily through two main business segments: Research and Development (R&D) and Commercialization.

Research and Development (R&D)

The R&D segment focuses on the discovery and preclinical and clinical development of monoclonal antibodies and other therapeutic modalities.

Commercialization

The Commercialization segment focuses on the distribution and marketing of the company's approved therapies. This segment also focuses on building partnerships with local and regional distributors to maximize access to its products in diverse geographical markets.

Business Strategy

The company has developed a multifaceted business strategy designed to establish a solid presence in the biopharmaceutical landscape while addressing the diverse needs of oncology patients. The company aims to enhance its market position by concentrating on innovation, strategic collaborations, pipeline development, and strengthening its operational capabilities.

At the core of the company's strategy is a focus on innovation, driving advancements in therapeutic development by leveraging technologies and methodologies. The company invests significantly in its R&D efforts, striving to identify and commercialize next-generation monoclonal antibodies and other therapeutic modalities. The company recognizes the necessity of accelerating drug development timelines.

Recognizing the competitive nature of the biopharmaceutical industry, the company actively pursues strategic collaborations with other companies, research institutions, and academic organizations. These partnerships augment the company's capabilities, enabling it to tap into external expertise and resources crucial for advancing its product pipeline.

Products and Services

The company offers a diverse range of products and services centered around the development of innovative therapies for oncology. The flagship product in the company's portfolio is ivonescimab (AK112), a bispecific antibody designed to target both PD-1 and VEGF, which is currently undergoing evaluation in clinical trials for several types of cancer.

In addition to ivonescimab, the company's pipeline includes several other investigational drugs at various stages of clinical development, focusing on hematological malignancies and solid tumors.

The company's research services extend beyond drug development, as it collaborates with partners to provide expertise in various aspects of preclinical and clinical development. The company assists in study design, regulatory submissions, and post-marketing surveillance.

Moreover, through its commercialization efforts, the company provides access to its approved therapies.

Geographical Markets Served

The company has strategically positioned its operations to serve multiple geographical markets, primarily focusing on the Asia-Pacific region.

Customers

The company has built a diverse customer base primarily composed of commercial customers and distributors. These customers include hospitals, oncology treatment centers, and healthcare providers who utilize the company's innovative therapies in clinical settings.

The strategic relationship with its largest customer, SUMMIT, has been instrumental in bolstering the company's revenue and market presence. The company serves a significant number of customers across multiple geographical regions, focusing on delivering accessible healthcare solutions to patients in need of advanced oncology therapies.

Sales and Marketing

The company employs a comprehensive sales and marketing strategy tailored to the specialized nature of its biopharmaceutical products. The company utilizes a multi-channel distribution approach, partnering with various stakeholders to optimize access to its therapies within healthcare markets. Key distribution partners include hospitals, clinics, oncology centers, and wholesalers.

The marketing strategy emphasizes educating healthcare professionals about the company's products. The sales team is equipped with in-depth product knowledge and clinical information, allowing for meaningful interactions with medical practitioners.

In addition to direct sales efforts, the company engages in digital marketing, utilizing online platforms and social media channels to reach broader audiences.

Regulations

The company is committed to compliance with the regulatory frameworks imposed by health authorities, including the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA).

History

Akeso, Inc. was founded in 2012. The company was incorporated in 2019.

Akeso Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Industry Revenues:** - Biopharmaceutical Research and Development: approx. 70% - Manufacturing and Distribution of Medications: approx. 30% **TOP 3 Markets:** - China: approx. 60% - USA: approx. 25% - Europe: approx. 10% Akeso, Inc. is a leading biopharmaceutical company specializing in the rese...

At which locations are the company’s products manufactured?

**Production sites of Akeso, Inc.:** Akeso, Inc. mainly produces its products in China. The company has several production facilities in the country that specialize in the manufacturing of biopharmaceutical products. These production sites are strategically positioned in China to ensure proximity...

What strategy does Akeso pursue for future growth?

**Focus on R&D Investments:** 30% of Revenue (2024) **Expansion of Product Pipeline:** 15 New Clinical Studies Planned for 2025 **International Expansion:** New Partnerships in Europe and North America (2024) Akeso, Inc. is pursuing a growth strategy that heavily focuses on research and dev...

Which raw materials are imported and from which countries?

**Main raw materials:** Biopharmaceutical active ingredients, chemicals for drug manufacturing **Countries of origin:** USA, Germany, China Akeso, Inc. is a biopharmaceutical company specializing in the development and production of antibody therapies. For the production of these therapies, the co...

How strong is the company’s competitive advantage?

**Market Share in Immunooncology:** Estimated 10% (2025) **R&D Investments:** Over 30% of revenue (2024) **Drug Pipeline:** 20+ in various stages of development (2025) Akeso, Inc. has established itself as a significant player in the field of immunooncology, as evidenced by an estimated m...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Estimated 45% (2025) **Insider Buys/Sells:** No significant changes in the last quarter (2025) The institutional investor share in Akeso, Inc. is estimated to be around 45%. This demonstrates a strong confidence from institutional investors in the company and its...

What percentage market share does Akeso have?

**Market share of Akeso, Inc.:** Estimate: 3-5% (2025) **Top competitors and their market shares:** 1. **Roche Holding AG:** 15% 2. **Novartis AG:** 12% 3. **Bristol-Myers Squibb:** 10% 4. **Merck & Co., Inc.:** 9% 5. **Pfizer Inc.:** 8% 6. **Johnson & Johnson:** 7% 7. **AstraZeneca:** 6% 8...

Is Akeso stock currently a good investment?

**Revenue Growth:** 22% (2024) **Research and Development Expenses:** 35% of Revenue (2024) **Pipeline:** 10 Products in Clinical Trials (2025) Akeso, Inc. achieved an impressive revenue growth of 22% in 2024, indicating strong demand for their biopharmaceutical products. The company continues to h...

Does Akeso pay a dividend – and how reliable is the payout?

**Dividend:** No payout (as of 2025) Akeso, Inc. is a biopharmaceutical company that focuses on the research and development of innovative therapies. Until 2025, the company has not distributed any dividends to its shareholders. This is typical for companies in the biotechnology industry, which oft...

New support ticket

Explore

Akeso Stock Value

Akeso Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Akeso do?

Akeso Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Akeso Stock Value

Akeso Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Akeso do?

Akeso Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.